Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors
Leveraging the R&D platform to broaden pipeline of offerings
TEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors.
Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).
The patent protection of new disease specific and patient specific cannabinoid compositions and treatment protocols has already begun, with these four patent applications filed this month alone, with several and more in progress.
Dr. Eyal Ballan, CTO and Co-Founder, said: "Cannabics is broadening its potential offerings to the healthcare industry. We believe that the company's expertise in clinical evaluation of cannabinoid formulations has now been brought to bear in designing specific drugs and treatments which will potentially benefit many patients globally."
About Cannabics
Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a
U.S-based public company that is developing a platform which
leverages novel drug-screening tools and artificial intelligence to
create cannabinoid-based therapies for cancer that are more
suitable to a patient's profile. By developing tools to assess
effectiveness on a personalized basis, Cannabics is helping to move
cannabinoids into the future of cancer therapy. The company's
R&D is based in Israel, where it is licensed by the
Ministry of Health to conduct scientific and clinical research on
cannabinoid formulations and Cancer. For more information,
please visit www.cannabics.com.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram: @Cannabics_Pharmaceuticals.
Disclaimer:
Certain statements
contained in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include but are not limited to statements
identified by words such as "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "targets," "projects" and similar
expressions. For example, we are using forward-looking statements
when we discuss the belief that our clinical experience and
personalization platform may allow for personalized cannabinoid
solutions for conditions and syndromes such as Alcohol Withdrawal
Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic
non-epileptic seizures (PNES) and Drug-induced tremors, found as
extrapyramidal side effects (EPSE), the potential for the
filing of new patent applications, and the belief that our
expertise in clinical evaluation of cannabinoid formulations has
now been brought to bear in designing specific drugs and treatments
which will potentially benefit many patients globally. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives, the
effect of any competitive products, our ability to license and
protect our intellectual property, our ability to raise additional
capital in the future that is necessary to maintain our business,
changes in government policy and/or regulation, potential
litigation by or against us, any governmental review of our
products or practices, as well as other risks discussed from time
to time in our filings with the Securities and Exchange Commission.
We undertake no duty to update any forward-looking statement or any
information contained in this press release or in other public
disclosures at any time. Finally, the investing public is reminded
that the only announcements or information about Cannabics
Pharmaceuticals Inc. which are condoned by the Company must emanate
from the Company itself and bear our name as its source.
For more information about
Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1 (877) 424-2429
[email protected]
http://www.cannabics.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-files-four-new-provisional-patent-applications-for-cannabinoid-based-drugs-and-treatments-for-non-epileptic-seizures-and-tremors-300787607.html